Héctor Tejero
TítolCitada perAny
Core circadian clock genes regulate leukemia stem cells in AML
RV Puram, MS Kowalczyk, CG de Boer, RK Schneider, PG Miller, ...
Cell 165 (2), 303-316, 2016
802016
Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections
C Perales, R Agudo, H Tejero, SC Manrubia, E Domingo
PLoS pathogens 5 (11), e1000658, 2009
682009
Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis
AM Ortega-Prieto, J Sheldon, A Grande-Pérez, H Tejero, J Gregori, J Quer, ...
PloS one 8 (8), e71039, 2013
462013
Effect of lethality on the extinction and on the error threshold of quasispecies
H Tejero, A Marín, F Montero
Journal of theoretical biology 262 (4), 733-741, 2010
262010
Treatment of pancreatic cancer patient–derived xenograft panel with metabolic inhibitors reveals efficacy of phenformin
NV Rajeshkumar, S Yabuuchi, SG Pai, E De Oliveira, JJ Kamphorst, ...
Clinical Cancer Research 23 (18), 5639-5647, 2017
232017
A molecular hypothesis to explain direct and inverse co-morbidities between Alzheimer’s Disease, Glioblastoma and Lung cancer
J Sánchez-Valle, H Tejero, K Ibáñez, JL Portero, M Krallinger, ...
Scientific reports 7 (1), 4474, 2017
222017
Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection
H Moreno, H Tejero, JC de la Torre, E Domingo, V Martín
PloS one 7 (3), e32550, 2012
182012
Theories of lethal mutagenesis: from error catastrophe to lethal defection
H Tejero, F Montero, JC Nuño
Quasispecies: From Theory to Experimental Systems, 161-179, 2015
152015
The relationship between the error catastrophe, survival of the flattest, and natural selection
H Tejero, A Marín, F Montero
BMC evolutionary biology 11 (1), 2, 2011
142011
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data
E Piñeiro-Yáñez, M Reboiro-Jato, G Gómez-López, J Perales-Patón, ...
Genome medicine 10 (1), 41, 2018
112018
Pancreas cancer precision treatment using avatar mice from a bioinformatics perspective
J Perales-Patón, E Piñeiro-Yañez, H Tejero, PP López-Casas, M Hidalgo, ...
Public health genomics 20 (2), 81-91, 2017
52017
Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer
B Paumard‐Hernández, O Calvete, L Inglada Pérez, H Tejero, ...
International journal of cancer 143 (8), 1954-1962, 2018
42018
Characteristic time in quasispecies evolution
A Marín, H Tejero, JC Nuno, F Montero
Journal of theoretical biology 303, 25-32, 2012
42012
Targeted sequencing reveals low-frequency variants in epha genes as markers of paclitaxel-induced peripheral neuropathy
M Apellániz-Ruiz, H Tejero, L Inglada-Pérez, L Sánchez-Barroso, ...
Clinical Cancer Research 23 (5), 1227-1235, 2017
32017
Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer
J Forés-Martos, F Catalá-López, J Sánchez-Valle, K Ibáñez, H Tejero, ...
Molecular autism 10 (1), 17, 2019
12019
The advantage of arriving first: characteristic times in finite size populations of error-prone replicators
A Marín, H Tejero, JC Nuño, F Montero
PloS one 8 (12), e83142, 2013
12013
vulcanSpot: a tool to prioritize therapeutic vulnerabilities in cancer
J Perales-Patón, TD Domenico, C Fustero-Torre, E Piñeiro-Yáñez, ...
Bioinformatics, 2019
2019
Unveiling the molecular basis of disease co-occurrence: towards personalized comorbidity profiles
J Sanchez-Valle, H Tejero, JM Fernandez, D Juan, S Capella, ...
bioRxiv, 431312, 2018
2018
Abstract A22: PanDrugsDB: Identifying druggable genetic dependencies for personalized cancer therapy
E Piñeiro-Yáñez, M Reboiro-Jato, J Perales-Patón, D Glez-Peña, ...
Molecular Cancer Therapeutics 14 (12 Supplement 2), A22-A22, 2015
2015
Mutación y extinción.
HT Franco, FM Carnerero
Universidad Complutense de Madrid, 2012
2012
En aquests moments el sistema no pot dur a terme l'operació. Torneu-ho a provar més tard.
Articles 1–20